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 Implication for health policy/practice/research/medical education:
 Although more people of  in developing counties protective to HAV infection ,but in recent decade  health improvements caused 
reduced its immunity in children so adult prone to life threatening infection ,therefore health austerities  should be considered 
vaccination strategy for HAV in the future years also in developed countries HAV vaccination for children should be continued. 
Hepatitis A virus (HAV) infection is one of the most common causes of acute hepatitis 
and it is a serious health problem worldwide. HAV infection is a vaccine preventable 
disease that can produce the lifelong immunity seen in many developed countries with 
the vaccination schedule administered to children; however this vaccine is not used 
in developing countries at the present time. Improvements in food and water hygiene 
have caused a displacement of hepatitis A infection from children to adults which has 
increased mortality rates. Therefore evaluation of HAV immunity levels can help health 
authorities develop polices for prophylaxis especially in developing countries.
Copyright  c 2011 Kowsar M. P. Co. All rights reserved. 
The hepatitis A virusis a small non-enveloped RnA virus 
of the Picornaviridae family that causes more than 1.5 mil-
lion cases of hepatitis throughout the world, and it is one 
of the most common causes of acute hepatitis as well as be-
ing an important worldwide health problem according to 
Vilibic-Cavlek et al. (1). Although Croatia appears to be a low 
prevalence HAV infection region, it is similar to other de-
veloped countries so the risk of a HAV outbreak is high and 
prophylaxis  should  be  considered  because  community 
immunity is correspondingly low and prone to outbreaks 
(1). Although evaluation of immunity is important in de-
veloping countries it seems that a study of HAV immunity 
in Croatia is not warranted and universal vaccination of 
children against HAV infection is more cost effective than 
an evaluation of immunity, the opposite was found in a 
study of HAV in Iran (2). on the other hand, nearly all of 
the older age groups in developing countries are immune 
to HAV and therefore are not prone to HAV infections, this 
relates to a study by Tanjana et al. By contrast in Iran the 
immunity of children to HAV is higher than in Croatia and 
universal vaccination is not as cost effective as an evalua-
tion of people’s immunity especially those in close contact 
with the disease, then prophylaxis especially with immune 
globulin is indicated (1-3).
Hepatitis A virus is transmitted through fecal material 
with the most common route being orally and outbreaks 
can occur in closed populations which have crowded liv-
ing conditions (4).  In developing countries improvements 
in both hygiene and the sanitation of food and water have 
caused a decrease in the prevalence of HAV infections simi-
lar to that of developed countries producing low levels of 
HAV immunity in their children. A study by Tanjana et al. 
showed that immunity levels in children under 15 years of 
age have reduced from 18.7%  to 5.6% so in the near future all 
children in the world will progress to non-immune levels 
of HAV, therefore public health managers should keep vac-
cination of children in mind (1, 5, 6). In most geographical 
regions men are at higher risk than women of contract-956 Evaluation of Hepatitis A Immunity
Hepat Mon. 2011;11(12):955-957
Ghorbani GA et al.
ing HAV infections because they have higher occupational 
risks including unpleasant work involving contaminated 
sewage and more men work outside of the home and the 
food and water that they eat may be unhealthy don’t re-
semble to study of tanjana, so the use of prophylaxis for 
HAV infections is more important for men (7, 8).
The highest number of asymptomatic HAV infection out-
breaks occurred in developing countries while symptom-
atic sporadic infections were seen in developed countries 
(9, 10). HAV infections are often acute and relief from symp-
toms occurs in a short time but sometimes prolonged or 
relapsing hepatitis is induced. The clinical spectrum of 
HAV  infection  ranges  from  asymptomatic  to  fulminant 
hepatitis with complications and atypical manifestations 
that may be life threatening in adulthood and the elderly 
(9, 11). In a study by Vilibic-Cavlek et al. who also showed this 
subject and therefore paradoxically symptomatic hepatitis 
A infections were not seen in developing countries because 
more infections occur in children and vice versa symptom-
atic HAV infections are seen more often in developed coun-
tries due to the increased numbers of infections occurring 
in adults (12). This study agreed with Vilibic-Cavlek et al. 
that evaluating immunity in children could determine the 
best time for vaccination. Due to improved living condi-
tions in recent years immunity against HAV is diminishing 
so both developed and developing countries are at high 
risk for this infection, like Croatia, particularly in children 
(6, 13).
Hepatitis A infection is a vaccine preventable disease, 
this vaccine can induce lifelong immunity and is used in 
many developed countries, but this vaccine is not yet read-
ily available in some developing countries (7, 8, 13). The 
vaccine has a high level of immunogenicity that in some 
cases reaches 100% sero-protection levels and it can control 
outbreaks  in  overcrowded,  susceptible  populations  (13). 
The two main ways that HAV can be prevented is by pas-
sive immunoprophylaxis and active immunoprophylaxis 
through vaccination (3). passive prophylaxis can be done 
with immune globulin for a short time pre- and post-ex-
posure to the hepatitis A virus and it can be used any time 
that a vaccine is not available. Centers for Disease Control 
and Prevention (CDC) also currently advocates that vac-
cine or immune globulin can be used as a post-exposure 
prophylaxis (13, 14). With exposure of a person to the virus 
whether they are suspected to be immune or not, a prophy-
laxis can be given to provide immunity to the HAV (2, 8). 
Moreover, immunoglobulin is effective as a vaccine but it 
is not approved for general prevention purposes, therefore 
for mass prophylaxis vaccination is advocated (13). In devel-
oping countries such as Iran following improvements in 
food and water hygiene, children’s immunity has reduced, 
therefore hepatitis A vaccination should be considered 
and an immune survey should be done every few years to 
help health managers decide when to provide universal 
vaccination against the HAV (14, 15). epidemiology mea-
sures that produce information about HAV infection lev-
els in different parts of the world is important for health 
authorities in order to provide prevention policies of HAV 
infection rates especially in developing countries (16).
Conclusion
Ultimately improvements in the hygiene of food and 
water  have  caused  the  displacement  of  HAV  infections 
from children to adult populations which has increased 
the mortality rate. Therefore in conformity with the ad-
vice from Vilibic-Cavlek et al. children in developed coun-
tries warrant evaluation of their immunity levels as well 
as those in developing countries until health authorities 
can suggest a time for prophylaxis. However in developed 
countries because the seroprevalence of HAV infections is 
much lower than in children of developing countries, it 
seems that vaccination against the HAV should be consid-
ered for all children. 
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